Business, energy, technology, markets and global industry news from Business News Today

Teva Pharmaceutical Industries

PharmaDeviceNews Teva Pharmaceutical Industries
Editorial infographic highlighting Medincell’s second FDA-approved drug, Weltruza, featuring an injectable medicine, FDA approval symbol, U.S. launch map and graphics illustrating clinical evidence, royalty potential and commercial outlook.
Pharma & Biotech

Can Weltruza become Medincell’s next growth driver after Uzedy commercial success?

Medincell gains a second FDA-approved drug as Teva prepares Weltruza's U.S. launch. See the clinical evidence, royalties and commercial outlook.

Read More
Infographic showing FDA approval of Teva’s Weltruza, a monthly subcutaneous olanzapine that requires no loading doses, oral supplementation or post-injection monitoring.
Pharma & Biotech

Teva wins FDA approval for Weltruza as monthly olanzapine changes schizophrenia LAI equation

Teva’s Weltruza wins FDA approval as a monthly subcutaneous olanzapine without loading doses, oral supplementation or post-injection monitoring.

Read More
Representative image: Bone imaging and oncology treatment planning illustrate Teva’s FDA approval of DEGEVMA, a denosumab biosimilar to Xgeva for cancer-related bone disease.
Pharma & Biotech

Teva wins FDA approval for DEGEVMA biosimilar across all Xgeva indications

FDA approves Teva’s DEGEVMA as an Xgeva biosimilar across oncology bone-disease indications, expanding its U.S. denosumab portfolio.

Read More
Teva Pharmaceutical Industries’ once-monthly TEV-’749 could make long-acting olanzapine more practical if FDA review supports use without the three-hour post-injection monitoring required for existing olanzapine depot therapy. Representative image.
Features & Analysis

Teva saw no PDSS across 3,470 injections. Could TEV-’749 finally make long-acting olanzapine practical?

Teva Pharmaceutical Industries has reported new long-term data for once-monthly subcutaneous TEV-’749 ahead of an expected fourth-quarter FDA decision. Its competitive proposition is not a new antipsychotic mechanism, but an attempt to combine established olanzapine efficacy with long-acting dosing without the post-injection monitoring burden that has constrained the existing olanzapine depot.

Read More
Pharma & Biotech

Teva TEV-408 protects against gluten-induced intestinal damage in Phase 2a celiac trial

Teva’s TEV-408 met the primary endpoint in a 50-patient Phase 2a celiac disease trial, significantly reducing gluten-induced intestinal damage while also limiting inflammatory-cell increases and gastrointestinal symptoms.

Read More
Representative image: Injectable inflammatory bowel disease treatment devices illustrate Alvotech’s AVT80 program as the FDA reviews its proposed interchangeable subcutaneous Entyvio biosimilar for ulcerative colitis and Crohn’s disease.
Pharma & Biotech

Alvotech advances dual Entyvio biosimilar strategy as FDA accepts subcutaneous AVT80 application

FDA accepts Alvotech’s AVT80 application for a subcutaneous Entyvio biosimilar, expanding its vedolizumab strategy alongside Teva.

Read More
FDA acceptance and Priority Review of Teva Pharmaceutical Industries Limited’s ecopipam New Drug Application follow Phase 3 data showing a 53% reduction in the risk of tic relapse among pediatric responders, strengthening the treatment’s regulatory path. Representative image.
Pharma & Biotech

Teva moves first-in-class ecopipam toward FDA decision after pediatric Phase 3 validates D1 receptor blockade

FDA has accepted Teva’s ecopipam NDA with Priority Review after Phase 3 treatment reduced the risk of tic relapse by 53% among pediatric responders.

Read More
A representative image illustrating Teva Pharmaceutical Industries’ ecopipam program as the FDA grants Priority Review for the investigational pediatric Tourette syndrome treatment following positive Phase 3 relapse-prevention data.
Pharma & Biotech

Teva’s ecopipam reaches FDA Priority Review after positive Phase 3 Tourette data

FDA grants Priority Review to Teva’s ecopipam after Phase 3 data showed a 53% lower Tourette relapse risk. See what the 2027 decision could mean.

Read More
Teva Pharmaceutical Industries and Polpharma Biologics are advancing PB018, a proposed Ocrevus biosimilar for multiple sclerosis, under a global licensing agreement covering major pharmaceutical markets. Representative image.
Pharma & Biotech

Teva wants a slice of Roche’s CHF 7bn Ocrevus franchise, but PB018 still has a long road ahead

Teva gains broad rights to PB018 as Polpharma Biologics advances an Ocrevus biosimilar into clinical development for multiple sclerosis.

Read More
Representative image: Biologic vial and infusion setup for multiple sclerosis care, highlighting Teva Pharmaceutical Industries’ Polpharma Biologics deal for a proposed ocrelizumab biosimilar.
Pharma & Biotech

Teva and Polpharma Biologics sign global ocrelizumab biosimilar licensing deal

Teva Pharmaceutical Industries Ltd. has secured exclusive global commercialization rights to Polpharma Biologics’ proposed biosimilar to Ocrevus ocrelizumab for multiple sclerosis, covering both intravenous and subcutaneous formulations upon regulatory approval. Polpharma Biologics will remain responsible for development and manufacturing, while Teva will handle regulatory submissions and commercialization across major markets including the United States, Europe,

Read More